PI-RADS评分在Gleason 3+3主动监测入选中的作用:一项诊断性meta分析
该诊断性meta分析纳入5项研究共834例经PRIAS标准定义的主动监测候选者,评估PI-RADS 4或5分预测根治性前列腺切除术后不良病理特征的效能。汇总敏感度0.77、特异度0.63、阳性预测值0.72、阴性预测值0.68、诊断比值比6,曲线下面积0.77。结论认为PI-RADS 4或5分者即使符合当前主动监测标准也可能不适合主动监测,而PI-RADS≤3分者相对安全。
要点
- PI-RADS 4或5分预测不良病理的汇总敏感度0.77、特异度0.63。
- 符合PRIAS标准的主动监测候选者中,PI-RADS 4或5分者可能不适合主动监测。
- PI-RADS≤3分者入选主动监测相对安全。
核心结论
- 符合当前主动监测标准的候选者中,PI-RADS 4或5分者可能不适合主动监测。
- PI-RADS≤3分者入选主动监测相对安全。
研究设计与样本
- 诊断性meta分析,检索Cochrane CENTRAL、PubMed和Embase至2018年6月。
- 纳入5项提供PI-RADS评分与病理结果诊断数据的研究,共834例患者。
- 所有主动监测候选者均按PRIAS标准定义。
主要发现
- PI-RADS 4或5分预测主动监测候选者根治性前列腺切除术后不良病理特征的汇总敏感度0.77(95%CI 0.71-0.82)。
- 汇总特异度0.63(95%CI 0.55-0.71),阳性预测值0.72(95%CI 0.64-0.79),阴性预测值0.68(95%CI 0.63-0.73)。
- 汇总诊断比值比6(95%CI 4-8),SROC曲线下面积0.77(95%CI 0.73-0.80)。
- 异质性P值<0.01;病理结局和直肠内线圈 contributed to 敏感度异质性。
- 支持PI-RADS v2优于v1的证据尚不充分。
关键数值与推荐
- PI-RADS 4或5分预测不良病理:敏感度0.77(95%CI 0.71-0.82),特异度0.63(95%CI 0.55-0.71)。
- 阳性预测值0.72(95%CI 0.64-0.79),阴性预测值0.68(95%CI 0.63-0.73),诊断比值比6(95%CI 4-8)。
- SROC曲线下面积0.77(95%CI 0.73-0.80)。
临床怎么用
- 对符合PRIAS标准的主动监测候选者,若PI-RADS为4或5分,应警惕不良病理可能,考虑不适合主动监测。
- PI-RADS≤3分者可相对安全地入选主动监测。
局限性
- 仅纳入5项研究,样本量834例。
- 异质性P值<0.01,病理结局和直肠内线圈影响敏感度异质性。
- 支持PI-RADS v2优于v1的证据尚不充分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The contemporary active surveillance (AS) criteria may result in an unsatisfactory misclassification rate, which may delay curative treatment for prostate cancer patients. The magnetic resonance imaging (MRI), not included in any AS criteria, provides useful information for prostate cancer diagnosis. Our goal is to evaluate the diagnostic performance of Prostate Imaging Reporting and Data Systems (PI-RADS) score, a standardized MRI reporting system, in AS candidates enrollment. METHODS: We searched Cochrane CENTRAL, PubMed, and Embase for pertinent studies through June 2018. The standard methods recommended for meta-analyses of diagnostic evaluation were employed. We draw the summary receiver operating characteristic (SROC) curve. Meta-regression analysis was performed to evaluate the effects of confounding factors. RESULTS: From the resulting 168 studies, 5 provided the diagnostic data on PI-RADS score and pathological results; 834 patients were included. All AS candidates in these studies were defined by Prostate Cancer Research International: Active Surveillance (PRIAS) criterion. The pooled estimates of PI-RADS 4 or 5 on adverse pathological features at radical prostatectomy (RP) among AS candidates were: sensitivity, 0.77 (95% confidence interval (CI), 0.71-0.82); specificity, 0.63 (95% CI, 0.55-0.71); positive predictive value, 0.72 (95% CI, 0.64-0.79); negative predictive value, 0.68 (95% CI, 0.63-0.73); and diagnostic odds ratio, 6 (95% CI, 4-8). The SROC curve was positioned toward the desired upper left corner of the curve, the area under the curve was 0.77 (95% CI, 0.73-0.80). The P-value for heterogeneity was <0.01. The pathological outcomes and endorectal coils contributed to the heterogeneity of sensitivity. The evidences supporting the advantage of PI-RADS v2 over v1 were not sufficient yet. CONCLUSION: AS candidates with PI-RADS 4 or 5 may be unsuitable for AS even though they fulfill current AS criteria. Those with PI-RADS 3 or less indicated relative safety for AS enrollment.
引用
- Zhai L, Fan Y, Meng Y, et al. The role of Prostate Imaging Reporting and Data System score in Gleason 3 + 3 active surveillance candidates enrollment: a diagnostic meta-analysis. Prostate Cancer Prostatic Dis. 2018. PMID: 30429594. doi:10.1038/s41391-018-0111-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。